:: Home   :: Contact ICare   :: Site Map          
 | Home | About ICare | Research | CTR Library | Register | Contact ICare
Lung Cancer News Pg1
Lung Cancer Breakthrough News

Archive 1

  November 09, 2009
ASTRO: Stereotactic Radiation Halts Spread of Lung CA
  By Charles Bankhead, Executive Editor, MedPage Today

CHICAGO -- Stereotactic body radiation contained early-stage, medically inoperable lung cancer at its site of origin in all but one patient involved in a small clinical trial reported here.     < READ MORE>

  Jan 29, 2009
STS: Smoking Complicates But Should Not Delay Lung Cancer Surgery
  By Peggy Peck, Executive Editor, MedPage Today

SAN FRANCISCO, Jan. 29 -- Lung cancer patients who smoke have a higher risk of dying during pulmonary resection and are more likely to develop postoperative complications, but surgery should proceed without delay, a researcher said here.     <READ MORE>

  Jan 27, 2009
STS: Lung Cancer Survival Best When Thoracic Surgeon Wields Scalpel
  By Peggy Peck, Executive Editor, MedPage Today

SAN FRANCISCO, Jan. 27 -- Lung cancer patients with resectable lesions had an 11% lower 5-year mortality risk when the surgery was performed by general thoracic surgeon, researchers said here.     <READ MORE>

  Nov 14, 2008
CTS: High Lung Cancer Response Rate Seen with Three-Drug Regimen Plus Cetuximab
  By Ed Susman, Contributing Writer, MedPage Today

CHICAGO, Nov. 14 -- Augmenting the standard therapy for non-small-cell lung cancer with cetuximab (Erbitux) is both safe and surprisingly effective, researchers said here.     <READ MORE>

  Nov 14, 2008
CTS: Still Unclear Why Part of Drug Duo Greater than Sum in NSCLC
  By Ed Susman, Contributing Writer, MedPage Today

CHICAGO, Nov. 14 -- Oncologists are still trying to figure out why the one-two combination of bevacizumab (Avastin) and erlotinib (Tarceva) leads to a punchless overall survival benefit in non-small-cell lung cancer.    <READ MORE>

  Nov 17, 2008
CTS: African-American Lung Cancer Patients Lack Key Mutation
  By Ed Susman, Contributing Writer, MedPage Today

CHICAGO, Nov. 17 -- The non-small-cell lung cancer tumors of African-Americans are significantly less likely to have a key mutation of the epidermal growth factor receptor (EGFR) gene, possibly affecting treatment choices.    <READ MORE>

  Nov 17, 2008
CTS: Gefitinib Superior to Chemotherapy Among Asians with Lung Cancer
  By Ed Susman, Contributing Writer, MedPage Today

CHCIAGO, Nov. 17 -- For carefully selected Asian patients with non-small-cell lung cancer, the tyrosine kinase inhibitor gefitinib (Iressa) significantly improved progression-free survival compared with the standard carboplatin (Paraplatin) and paclitaxel (Taxol), researchers reported here.     <READ MORE>

  Nov 18, 2008
CTS: Proton Therapy Reduces Bone Marrow Toxicity in Lung Cancer Patients
  By Ed Susman, Contributing Writer, MedPage Today

CHICAGO, Nov. 18 -- Non-small-cell lung cancer patients on chemotherapy who undergo treatment with proton beam radiation appear to suffer less bone marrow toxicity than those treated with conventional radiation therapy, researchers said here.    <READ MORE>

  Nov 18, 2008
CTS: Erlotinib Equally Effective Alone or in Combination Against Lung Cancer
  By Ed Susman, Contributing Writer, MedPage Today

CHICAGO, Nov. 18 -- There were no differences in overall survival between non-small-cell lung cancer patients treated with erlotinib (Tarceva) alone or in combination with standard chemotherapy, researchers found.   <READ MORE>

  Nov 18, 2008
CTS: Sorafenib Shows No Advantage in Non-Small-Cell Lung Cancer
  By Ed Susman, Contributing Writer, MedPage Today

CHICAGO, Nov. 18 -- It's two strikes against the oral multikinase inhibitor sorafenib (Nexavar) for treating advanced non-small-cell lung cancer in the ESCAPE trial.  <READ MORE>

  Oct 9, 2008
Analysis Questions Platinum Standard for Small-Cell Lung Cancer
  By Charles Bankhead, Staff Writer, MedPage Today

HOBART, Australia, Oct. 9 -- Platinum-based chemotherapy for small-cell lung cancer offers no better chance of survival than other regimens and causes substantially more toxicity, according to findings of a systematic review. <READ MORE>

  Oct 8, 2008
Lung Cancer Less Likely in Smokers Who Drink Red Wine
  By Kristina Fiore, Staff Writer, MedPage Today

PASADENA, Calif., Oct. 8 -- Drinking moderate amounts of red wine may offer some protection against lung cancer in men with a history of smoking, according to a prospective cohort study.  <READ MORE>

  Sept 25, 2008
ASTRO: Stereotactic Radiation Improves Local Control But Not Survival in NSCLC
  By Charles Bankhead, Staff Writer, MedPage Today

BOSTON, Sept. 25 -- Stereotactic body radiotherapy for inoperable early-stage non-small- cell lung cancer achieved "excellent" long-term local control and "encouraging" cause-specific survival but failed to boost overall survival, according to a small Scandinavian study reported here.  <READ MORE>

 

Sept 23, 2008
Drug Makers Warn of Liver and Kidney Risks with EGFR-Inhibitor

  By Johns Hopkins Kimmel Cancer Center (Press Release)

ROCKVILLE, Md., Sept. 23 -- The FDA said today that the makers of the cancer drug erlotinib (Tarceva) have reported two deaths -- one from hepatorenal syndrome and one from rapidly progressing liver failure -- among patients taking the agent.    <READ MORE>

  July 2, 2008
Trapped Circulating Tumor Cells Track NSCLC Treatment
  By Crystal Phend, Staff Writer, MedPage Today

BOSTON, July 2 -- Patient response to non-small-cell lung cancer treatment can be assessed by capturing circulating tumor cells with a microchip, a small study showed.   <READ MORE>

  June 18, 2008
Prospective Evaluation of Lung Cancer Ablation Called Promising
  By Crystal Phend, Staff Writer, MedPage Today

PISA, Italy, June 18 -- Radiofrequency ablation of small lung tumors may yield outcomes that rival standard radiation for selected patients ineligible for surgery or other therapy, researchers found in a seven-center trial in Europe, the U.S., and Australia.   <READ MORE>

  June 6, 2008
ASCO: IGF Inhibitor Leads to High Response Rate in Squamous NSCLC
  By Peggy Peck, Executive Editor, MedPage Today

CHICAGO, June 6 -- In patients with advanced non-small-cell lung cancer, adding an insulin-like growth factor receptor inhibitor to chemotherapy significantly increased overall response and improved progression-free survival, according to results of a phase II study.   <READ MORE>

  June 5, 2008
ASCO: Little Support Seen for CT Lung Cancer Screening
  By Crystal Phend, Staff Writer, MedPage Today

CHICAGO, June 5 -- Controversy and lack of evidence for a mortality benefit have made physicians reluctant to embrace spiral computed tomography (CT) screening for lung cancer.   <READ MORE>

  June 5, 2008
ASCO: Advanced NSCLC Progression Slowed by Pemetrexed (Alimta)
  By Peggy Peck, Executive Editor, MedPage Today

CHICAGO, June 5 -- After primary chemotherapy, patients with advanced non-small-cell lung cancer had a significant improvement in progression-free survival with pemetrexed (Alimta) maintenance, a large multicenter study showed.   <READ MORE>

  June 5, 2008
ASCO: Extended Chemotherapy for NSCLC Yields Mixed Results
  By Peggy Peck, Executive Editor, MedPage Today

CHICAGO, June 5 -- For patients with non-small-cell lung cancer, extending their course of chemotherapy improves progression-free survival but not overall survival and at a cost of more adverse events and reduced quality of life, data from a meta-analysis suggest.   <READ MORE>

  June 5, 2008
ASCO: Sorafenib (Nexavar) Slows Progression in Heavily Treated NSCLC
  By Peggy Peck, Executive Editor, MedPage Today

CHICAGO, June 5 -- Patients with non-small-cell lung cancer who'd already had several courses of chemotherapy had significant slowing of progression when treated with sorafenib, according to results of a small intergroup trial.  <READ MORE>

  June 5, 2008
ASCO: Gefitinib (Iressa) Shows Benefit for NSCLC Adenocarcinomas
  By Peggy Peck, Executive Editor, MedPage Today

CHICAGO, June 5 -- In advanced non-small-cell lung cancer, disease progression slowed significantly when gefitinib (Iressa) was given after first-line chemotherapy, a large Japanese study showed. <READ MORE>

  June 5, 2008
ASCO: North American Trial Fails to Confirm Benefit for Irinotecan (Camptosar) in SCLC
  By Peggy Peck, Executive Editor, MedPage Today

CHICAGO, June 5 -- Irinotecan (Camptosar) plus cisplatin (Platinol) failed to demonstrate a survival benefit in a large North American trial of patients with extensive-stage small-cell lung cancer.  <READ MORE>

  June 2, 2008
ASCO: Genes Guide Early Stage NSCLC Treatment Decisions
  By Crystal Phend, Staff Writer, MedPage Today

CHICAGO, June 2 -- A genetic test may help determine which early stage non-small-cell lung cancer patients can be spared chemotherapy after surgery, researchers said here.  <READ MORE>

  June 1, 2008
ASCO: Cetuximab (Erbitux) Gives Extra Time to Advanced Lung Cancer Patients
  By Peggy Peck, Executive Editor, MedPage Today

CHICAGO, June 1 -- For advanced non-small-cell lung cancer, cetuximab (Erbitux) added to platinum-based chemotherapy increased median survival by five weeks, according to an international study.  <READ MORE>

  May 27, 2008
Gene Defect Doubles Risk of Lung Cancer
  By Michael Smith, North American Correspondent, MedPage Today

ROCHESTER, Minn., May 27 -- People with a common genetic mutation have up to twice the risk of lung cancer as do people without the variation, researchers here said.  <READ MORE>

  May 20, 2008
ASCO: Cox-2 Inhibitor Shows Chemopreventive Potential in Lung Cancer
  By John Gever, Staff Writer, MedPage Today

HOUSTON, May 20 -- Long-time smokers showed significant declines in a key marker of abnormal lung cell growth after taking the anti-inflammatory drug celecoxib (Celebrex) for three months, according to interim data from a study here.  <READ MORE>

  May 20, 2008
ATS: Blood Test Might Help NSCLC Diagnosis
  By Michael Smith, North American Correspondent, MedPage Today

TORONTO, May 20 -- The active genes in immune cells of patients with non-small cell lung cancer are different than those of healthy patients, a researcher said here.  <READ MORE>

  Apr 25, 2008
ELCC: Immunotherapy for NSCLC Well-Tolerated
  By Michael Smith, North American Correspondent, MedPage Today

GENEVA, April 25 -- An immune-boosting treatment for non-small-cell lung cancer patients with completely resected stage IB or II disease is safe and well tolerated, researchers said here.  <READ MORE>

Archive 1

 

:: 12 Element Approach ::
Explore and supplement your therapy with ICare's unique 12-Element approach to Patient Survival.

:: Breakthrough News ::
Breaking news on research for gentler, more effective therapies and information on lifesaving treatment options.

:: ICare Bulletin Board ::
View pertinent information regarding meetings and events pertaining to cancer patients. This is also a resource for contacting other patients about information and treatment options.

 
Lung Cancer News
Copyright ⓒ ICare.  All rights reserved.